Transgenic Expression of Intraneuronal A 42 But Not A 40 Leads to Cellular A Lesions, Degeneration, and Functional Impairment without Typical Alzheimer's Disease Pathology

D. Abramowski, S. Rabe, A. R. Upadhaya, J. Reichwald, S. Danner, D. Staab, E. Capetillo-Zarate, H. Yamaguchi, T. C. Saido, K.-H. Wiederhold, D. R. Thal, M. Staufenbiel
2012 Journal of Neuroscience  
An early role of amyloid-β peptide (Aβ) aggregation in Alzheimer's disease pathogenesis is well established. However, the contribution of intracellular or extracellular forms of Aβ to the neurodegenerative process is a subject of considerable debate. We here describe transgenic mice expressing Aβ1-40 (APP47) and Aβ1-42 (APP48) with a cleaved signal sequence to insert both peptides during synthesis into the endoplasmic reticulum. Although lower in transgene mRNA, APP48 mice reach a higher brain
more » ... ach a higher brain Aβ concentration. The reduced solubility and increased aggregation of Aβ1-42 may impair its degradation. APP48 mice develop intracellular Aβ lesions in dendrites and lysosomes. The hippocampal neuron number is reduced already at young age. The brain weight decreases during aging in conjunction with severe white matter atrophy. The mice show a motor impairment. Only very few Aβ1-40 lesions are found in APP47 mice. Neither APP47 nor APP48 nor the bigenic mice develop extracellular amyloid plaques. While intracellular membrane expression of Aβ1-42 in APP48 mice does not lead to the AD-typical lesions, Aβ aggregates develop within cells accompanied by considerable neurodegeneration.
doi:10.1523/jneurosci.4586-11.2012 pmid:22279212 pmcid:PMC6796269 fatcat:ciyhlehexjbjxcq4jld7xvqomm